57 completed, 13 terminated, 11 recruiting, 4 active not recruiting. 94 Phase 3, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 94 | Completed 57, Terminated 13, Recruiting 11, Active not recruiting 4, Unknown 4, Withdrawn 4, Not yet recruiting 1 |
| Phase 2 | 10 | Completed 6, Terminated 2, Unknown 2 |
Follow Embolism: new trials by email Literature Review of Embolism trials Research Report on Embolism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reduced-Dose Thrombolysis in Intermediate-Risk Pulmonary Embolism With High-Risk Features Alteplase, Standard Anticoagulation - Pulmonary Embolism | Phase 3 | Not yet recruiting | China National Center for Cardiovascular Diseases | 270 | 2026-11-01 | 2026-11-04 |
| Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers REGN7508, Apixaban - Venous Thromboembolism (VTE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 1600 | 2026-08-26 | 2026-11-05 |
| Percutaneous Embolectomy, Low Dose Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism (STRATIFY II) Ultrasound assisted Thrombolysis, Percutaneous Embolectomy, Heparin - Pulmonary Embolism | Phase 3 | Recruiting | Jesper Kjaergaard | 210 | 2026-06-17 | 2026-07-02 |
| The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity Aspirin, Low-molecular-weight heparin - Venous Thromboembolism, Postpartum Period | Phase 3 | Recruiting | University of Calgary | 8805 | 2026-06-04 | 2026-07-27 |
| Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable REGN7508, REGN9933, Placebo - Atrial Fibrillation (AF) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 2628 | 2026-04-03 | 2026-11-10 |
| REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis REGN7508, Placebo - Cancer-Associated Thrombosis (CAT) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 1120 | 2026-03-09 | 2026-11-05 |
| The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer Kinisoquin™, Placebo - Venous Thromboembolism, Metastatic Pancreatic Cancer | Phase 3 | Recruiting | Quercis Pharma AG | 480 | 2025-12-19 | 2026-02-02 |
| REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants REGN7508, Acetylsalicylic Acid (ASA), Placebo - Symptomatic Venous Thromboembolism (VTE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 2000 | 2025-11-24 | 2026-11-05 |
| ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty Prevention of Venous Thromboembolism, Placebo Oral Tablet - Hip Arthroplasty, Total, Prevention of Venous Thromboembolism | Phase 3 | Recruiting | Prof. Stavros Konstantinides, MD | 2932 | 2024-11-26 | 2025-01-16 |
| RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing Rivaroxaban 10 MG, Low Heparin Molecular Weight - Venous Thromboembolism, Deep Vein Thrombosis | Phase 3 | Recruiting | University Hospital, Angers | 1424 | 2024-07-19 | 2026-06-25 |
| Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism Non-immunogenic recombinant staphylokinase, Placebo - Pulmonary Embolism | Phase 3 | Recruiting | Supergene, LLC | 486 | 2024-05-23 | 2025-12-05 |
| Macitentan to Prevent PRVO Macitentan 10mg - Pulmonary Embolism | Phase 3 | Withdrawn | University of Maryland, Baltimore | 2024-05-01 | 2024-03-08 | |
| Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets Full-dose anticoagulant therapy (AC), Antiplatelet therapy (AP) - Venous Thromboembolic Disease | Phase 3 | Recruiting | Centre Hospitalier Universitaire de Saint Etienne | 1400 | 2023-08-16 | 2026-05-08 |
| Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy Anticoagulant Therapy, Catheter-Directed Therapy - Pulmonary Embolism | Phase 3 | Active not recruiting | NYU Langone Health | 500 | 2023-07-17 | 2026-10-28 |
| Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus Vitamin K antagonist, Direct oral anticoagulant - Intracardiac Thrombus, STEMI | Phase 3 | Active not recruiting | Centre Hospitalier Universitaire de Nīmes | 340 | 2023-05-15 | 2026-02-17 |
| A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Abelacimab, Dalteparin - Venous Thromboembolism, Deep Venous Thrombosis | Phase 3 | Terminated | Anthos Therapeutics, Inc. | 417 | 2022-09-27 | 2026-04-17 |
| A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE Abelacimab, Apixaban - Venous Thromboembolism, Deep Venous Thrombosis | Phase 3 | Terminated | Anthos Therapeutics, Inc. | 1150 | 2022-05-05 | 2026-02-23 |
| Pulmonary Embolism International THrOmbolysis Study-3 Alteplase, Placebo - Pulmonary Embolism | Phase 3 | Active not recruiting | Assistance Publique - Hôpitaux de Paris | 800 | 2021-08-04 | 2026-07-01 |
| Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19 Dimolegin, Clexane - COVID-19, Venous Thromboembolism | Phase 3 | Completed | PharmaDiall Ltd. | 399 | 2021-02-08 | 2022-01-11 |
| Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events Rivaroxaban 20 MG [Xarelto], Aspirin 300mg, Acenocoumarol Oral Tablet - Venous Thromboembolism, Anticoagulant-induced Bleeding | Phase 2 / Phase 3 | Completed | Instituto Mexicano del Seguro Social | 58 | 2021-01-03 | 2022-08-25 |
Showing 20 of 94. Sign in to see all of them.
Pulmonary Embolism (82) · Venous Thrombosis (51) · Venous Thromboembolism (37) · Thrombosis (13) · Thromboembolism (11) · Atrial Fibrillation (6) · Hemorrhage (5) · Neoplasms (5) · Stroke (4) · Arterial Occlusive Diseases (2) · COVID-19 (2) · Heart Failure (2) · Intermittent Claudication (2) · Intracranial Thrombosis (2)
Embolism and Thrombosis (94) · Vascular Diseases (94) · Cardiovascular Diseases (93) · Respiratory Tract Diseases (82) · Lung Diseases (81) · Thrombosis (43) · Thromboembolism (32) · Pathological Conditions, Signs and Symptoms (20) · Pathologic Processes (18) · Heart Diseases (10) · Brain Diseases (9) · Central Nervous System Diseases (9) · Nervous System Diseases (9) · Cerebrovascular Disorders (8)
Enoxaparin (15) · Warfarin (12) · apixaban (11) · Heparin (10) · Rivaroxaban (9) · Dalteparin (8) · Heparin, Low-Molecular-Weight (8) · Aspirin (6) · Fondaparinux (6) · Tissue Plasminogen Activator (6) · edoxaban (6) · acarboxyprothrombin (4) · Vena Cava Filters (3) · enoxaparin sodium (3) · MAA868 (2)
Bristol-Myers Squibb (5) · Assistance Publique - Hôpitaux de Paris (4) · Bayer (4) · Daiichi Sankyo (4) · McMaster University (4) · Regeneron Pharmaceuticals (4) · Sanofi (4) · Crux Biomedical (3) · GlaxoSmithKline (3) · ARCA Biopharma, Inc. (2) · Academic and Community Cancer Research United (2) · Anthos Therapeutics, Inc. (2) · Boston Scientific Corporation (2) · Centre Hospitalier Universitaire de Saint Etienne (2) · Daiichi Sankyo Co., Ltd. (2)
United States (44) · Canada (30) · France (28) · Spain (22) · Germany (21) · Italy (21) · Australia (19) · Belgium (19) · Denmark (19) · Netherlands (18) · Poland (18) · Austria (17) · Hungary (16) · Norway (16) · Sweden (16)
Jim Julian, MMath (3) · Takeshi Fuji (2) · Abass Alavi (1) · Agnes Y Lee, MD (1) · Akash Sharma, MD (1) · Alan Maisel, MD (1) · Alberto Conti, MD (1) · Alexander G Turpie, MB (1)
PMID 35570249, PMID 40163217, PMID 22863355, PMID 23279103, PMID 28617144, PMID 28762617, PMID 33857326, PMID 35876829, PMID 40925065, PMID 15262836, PMID 16531616, PMID 16926353, PMID 17498584, PMID 17723125, PMID 17855670, PMID 17855671, PMID 18838564, PMID 19233855, PMID 19293071, PMID 19348685, PMID 19657123, PMID 19854398, PMID 20206776, PMID 20211293, PMID 20448094, PMID 20516378, PMID 20934556, PMID 20950224, PMID 21083927, PMID 21175312, PMID 21359646, PMID 21703676, PMID 21830957, PMID 21861537, PMID 22077144, PMID 22130488, PMID 22172434, PMID 22284935, PMID 22371186, PMID 22398655, PMID 22402056, PMID 22431865, PMID 22449293, PMID 22450429, PMID 22621626, PMID 23212720, PMID 23318311, PMID 23388003, PMID 23500298, PMID 23525418
2023 (3), 2016 (2), 2025 (2), 2014 (1), 2018 (1), 2019 (1), P30CA015083 (1), R01HL085565 (1), R01HL095109 (1), R42HL086316 (1)